SELLAS Life Sciences Group, Inc. 8K

SELLAS Life Sciences reported Q1 2026 results and a corporate update, noting near-completion of events for its pivotal Phase 3 REGAL AML trial, progress of its SLS009 AML program, establishment of a $150 million ATM facility, and a strengthened cash position despite higher operating losses.

On May 12, 2026, SELLAS Life Sciences Group, Inc. reported its financial results for the quarter ended March 31, 2026 and provided a corporate update, highlighting that 78 of the 80 required events (deaths) have occurred in its pivotal Phase 3 REGAL trial of galinpepimut-S (GPS) in acute myeloid leukemia, with final analysis to occur after the 80th event, while also advancing its SLS009 (tambiciclib) program through ongoing dosing in an 80-patient Phase 2 first-line AML trial and presentation of supportive preclinical data, establishing a $150 million at-the-market equity program (with no sales to date), and reporting a net loss of $8.4 million on increased R&D and G&A expenses alongside a strengthened cash position of $107.1 million plus $7.5 million in warrant proceeds received in Q2 2026 to date.

Filing Facts

CIK

1390478

Ticker

SLS

Form

8K

Source Type

sec

Accession

0001390478-26-000009

Alert Tier

6